{"brief_title": "Study Evaluating rFIX; BeneFIX\u00ae in Hemophilia B", "brief_summary": "The primary objective of this clinical research study is to assess the safety and efficacy of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C \u22642%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor surgical procedures).", "condition": ["Hemophilia B"], "intervention_type": ["Drug"], "intervention_name": ["rFIX"], "criteria": "Inclusion Criteria: - Hemophilia B (FIX:C less than 2%) - Previous treatment of at least 150 exposure days using any FIX product - 12 years of age and older Exclusion Criteria: - The patient has a currently detectable factor IX inhibitor or a history of inhibitors. (A family history of inhibitors will not exclude the patient) - Known hypersensitivity to protein pharmaceuticals or agents related to the test article, e.g. hamster proteins - Patient has a genetic coagulation disorder other than hemophilia B", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Hemophilia A", "Hemophilia B"], "id": "NCT00093171"}